Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAM-LIRA: Liraglutide vs Colesevelam in Bile Acid Malabsorption
NCT03955575Phase 4Completed
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liraglutide in bile acid malabsorption (BAM) (2 arms). Primary endpoint: Change in stool frequency at 7 weeks. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
bile acid malabsorption (BAM)
Beyond the preview
Go deeper on NCT03955575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955575.